Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.